Download PDF
Semin Liver Dis 2015; 35(03): 349-354
DOI: 10.1055/s-0035-1562952
Diagnostic Problems in Hepatology
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

The Evolving Role of Nonalcoholic Fatty Liver Disease in Hepatic Neoplasia: Inflammatory Hepatocellular Adenoma in a Man with Metabolic Syndrome

Jay H. Lefkowitch
1   Department of Pathology and Cell Biology, Columbia University Medical Center, New York, New York
,
Liza V. Antony
2   Department of Pathology, St. Luke's Cornwall Hospital, Newburgh, New York
› Author Affiliations
Further Information

Publication History

Publication Date:
17 September 2015 (online)

    Permissions and Reprints

Abstract

Growing awareness of the spectrum of liver diseases related to nonalcoholic fatty liver disease (NAFLD) has drawn attention to the complex pathogenetic pathways that are operative in livers with macrovesicular steatosis and to the potential development of hepatocellular adenoma and hepatocellular carcinoma in unusual clinical settings. This report describes an older man with metabolic syndrome who developed a 3.9 cm. right lobe liver mass that on directed needle biopsy showed the features of an inflammatory hepatocellular adenoma, including immunostain positivity for serum amyloid A. The case highlights the many factors involved in the pathogenesis of liver tumors in the steatotic liver of NAFLD, particularly the interplay of inflammatory mediators, adiponectin and leptin, genomics and metabolomics, lipotoxicity, endotoxin, and hepatic stellate cells.

Keywords

nonalcoholic fatty liver disease - hepatocellular adenoma - hepatocellular carcinoma - metabolic syndrome - steatosis - fatty liver - noncirrhotic hepatocellular carcinoma
 

  • References

  • 1 Chang CY, Hernandez-Prera JC, Roayaie S, Schwartz M, Thung SN. Changing epidemiology of hepatocellular adenoma in the United States: review of the literature. Int J Hepatol 2013; 2013: 604860
    PubMedGoogle Scholar
  • 2 Bioulac-Sage P, Taouji S, Possenti L, Balabaud C. Hepatocellular adenoma subtypes: the impact of overweight and obesity. Liver Int 2012; 32 (8) 1217-1221
    CrossrefPubMedGoogle Scholar
  • 3 Bioulac-Sage P, Balabaud C, Zucman-Rossi J. Will the pathomolecular classification of hepatocellular adenomas improve their clinical management?. J Hepatol 2011; 55 (1) 8-10
    CrossrefPubMedGoogle Scholar
  • 4 Dongiovanni P, Romeo S, Valenti L. Hepatocellular carcinoma in nonalcoholic fatty liver: role of environmental and genetic factors. World J Gastroenterol 2014; 20 (36) 12945-12955
    CrossrefPubMedGoogle Scholar
  • 5 Scalera A, Tarantino G. Could metabolic syndrome lead to hepatocarcinoma via non-alcoholic fatty liver disease?. World J Gastroenterol 2014; 20 (28) 9217-9228
    PubMedGoogle Scholar
  • 6 Streba LAM, Vere CC, Rogoveanu I, Streba CT. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question. World J Gastroenterol 2015; 21 (14) 4103-4110
    CrossrefPubMedGoogle Scholar
  • 7 Dumas M-E, Kinross J, Nicholson JK. Metabolic phenotyping and systems biology approaches to understanding metabolic syndrome and fatty liver disease. Gastroenterology 2014; 146 (1) 46-62
    CrossrefPubMedGoogle Scholar
  • 8 Bioulac-Sage P, Blanc JF, Rebouissou S, Balabaud C, Zucman-Rossi J. Genotype phenotype classification of hepatocellular adenoma. World J Gastroenterol 2007; 13 (19) 2649-2654
    CrossrefPubMedGoogle Scholar
  • 9 Liu T-C, Vachharajani N, Chapman WC, Brunt EM. Noncirrhotic hepatocellular carcinoma: derivation from hepatocellular adenoma? Clinicopathologic analysis. Mod Pathol 2014; 27 (3) 420-432
    PubMedGoogle Scholar
  • 10 Ganz M, Bukong TN, Csak T , et al. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice. J Transl Med 2015; 13: 193
    CrossrefPubMedGoogle Scholar
  • 11 Fan Y, Fang X, Tajima A , et al. Evolution of hepatic steatosis to fibrosis and adenoma formation in liver-specific growth hormone receptor knockout mice. Front Endocrinol (Lausanne) 2014; 5: 218
    PubMedGoogle Scholar
  • 12 Pilati C, Letouzé E, Nault J-C , et al. Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation. Cancer Cell 2014; 25 (4) 428-441
    CrossrefPubMedGoogle Scholar
  • 13 Nault JC, Bioulac-Sage P, Zucman-Rossi J. Hepatocellular benign tumors-from molecular classification to personalized clinical care. Gastroenterology 2013; 144 (5) 888-902
    CrossrefPubMedGoogle Scholar
  • 14 Bioulac-Sage P, Cubel G, Balabaud C, Zucman-Rossi J. Revisiting the pathology of resected benign hepatocellular nodules using new immunohistochemical markers. Semin Liver Dis 2011; 31 (1) 91-103
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Campbell PT, Newton CC, Patel AV, Jacobs EJ, Gapstur SM. Diabetes and cause-specific mortality in a prospective cohort of one million U.S. adults. Diabetes Care 2012; 35 (9) 1835-1844
    CrossrefPubMedGoogle Scholar
  • 16 Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol 2012; 56 (6) 1384-1391
    CrossrefPubMedGoogle Scholar
  • 17 Guzman G, Brunt EM, Petrovic LM, Chejfec G, Layden TJ, Cotler SJ. Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis?. Arch Pathol Lab Med 2008; 132 (11) 1761-1766
    PubMedGoogle Scholar